Page 1024 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

Chapter 61

REFERENCES

1. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmaco- dosing in septic critically ill patients. Int J Antimicrob Agents.
kinetic and pharmacodynamic issues in the critically ill with 2006;28:122-127.
severe sepsis and septic shock. Crit Care Clin. 2011;27:19-34. 14. Lorente L, Jimenez A, Martin MM, et al. Clinical cure of
2. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics ventilator-associated pneumonia treated with piperacillin/
in the critically ill patient. Crit Care Med. 2009;37:840-851; tazobactam administered by continuous or intermittent infu-
quiz 59. sion. Int J Antimicrob Agents. 2009;33:464-468.
3. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoal- 15. Lee GC, Liou H, Yee R, et al. Outcomes of extended-infusion
buminaemia on optimizing antibacterial dosing in critically ill piperacillin-tazobactam: a retrospective analysis of critically ill
patients. Clin Pharmacokinet. 2011;50:99-110. patients. Clin Ther. 2012;34:2297-2300.
4. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: 16. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion
implications for antibacterial dosing in the critically ill. Clin piperacillin/tazobactam for documented Gram-negative infec-
Pharmacokinet. 2010;49:1-16. tions. Diagn Microbiol Infect Dis. 2009;64:236-240.
5. Nicolau DP. Optimizing outcomes with antimicrobial ther- 17. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert
apy through pharmacodynamic profiling. J Infect Chemother. Opin Pharmacother. 2008;9:23-37.
2003;9:292-296.
18. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the
6. Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetics carbapenems. Drugs. 2007;67:1027-1052.
of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Pharmacotherapy. 2003;23:988-991. 19. Ong CT, Kuti JL, Nightingale CH, et al. Emerging Pseudomonas
aeruginosa resistance: implications in clinical practice. Conn
7. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and Med. 2004;68:11-15.
pharmacoeconomics of a continuous-infusion piperacillin-
tazobactam program in a large community teaching hospital. 20. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant
Pharmacotherapy. 2002;22:471-483. Pseudomonas aeruginosa: risk factors and antibiotic suscepti-
bility patterns. Clin Infect Dis. 1997;25:1094-1098.
8. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic ini-
tial beta-lactam concentrations in select critically ill patients: 21. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-
association between augmented renal clearance and low trough cilastatin as initial monotherapy for febrile neutropenic patients.
drug concentrations. Chest. 2012;142:30-39. Antimicrob Agents Chemother. 1990;34:1336-1341.
9. Roberts JA, Kirkpatrick CM, Roberts MS, et al. First-dose and 22. Keel RA, Sutherland CA, Crandon JL, et al. Stability of doripe-
steady-state population pharmacokinetics and pharmacodynamics nem, imipenem and meropenem at elevated room temperatures.
of piperacillin by continuous or intermittent dosing in critically ill Int J Antimicrob Agents. 2011;37:184-185.
patients with sepsis. Int J Antimicrob Agents. 2010;35:156-163. 23. Crandon JL, Ariano RE, Zelenitsky SA, et al. Optimization of
10. Shikuma LR, Ackerman BH, Weaver RH, et al. Effects of treat- meropenem dosage in the critically ill population based on
ment and the metabolic response to injury on drug clearance: a renal function. Intensive Care Med. 2011;37:632-638.
prospective study with piperacillin. Crit Care Med. 1990;18:37-41. 24. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-
11. Kim MK, Xuan D, Quintiliani R, et al. Pharmacokinetic and based clinical pathway for empiric antibiotic choice in patients
pharmacodynamic profile of high dose extended interval piper- with ventilator-associated pneumonia. J Crit Care. 2010;25:69-77.
acillin-tazobactam. J Antimicrob Chemother. 2001;48:259-267. 25. Bulik CC, Quintiliani R, Pope JS, et al. Pharmacodynamics and
12. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin- tolerability of high-dose, prolonged infusion carbapenems in
tazobactam for Pseudomonas aeruginosa infection: clinical adults with cystic fibrosis—A review of 3 cases. Respir Med CME.
implications of an extended-infusion dosing strategy. Clin Infect 2010:146-149.
Dis. 2007;44:357-363. 26. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day
13. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy doripenem versus 10-day imipenem-cilastatin for ventilator-
of continuous infusion of piperacillin compared with intermittent associated pneumonia. Crit Care. 2012;16:R218.

Section05-O-ref.indd 1 1/20/2015 4:51:15 PM